Asset acquisition of Cook Medical's end-to-end lead management product portfolio strengthens Merit's existing electrophysiology and CRM business Asset acquisition projected to add approximately $40 million of revenue, on an annualized basis beginning in fiscal year 2025, with a solid growth profile serving an underpenetrated global lead management market Merit reaffirms full-year 2024 financial guidance previously issued on August 1, 2024, and updates fullyear 2024 financial guidance to include the projecte ...

Merit Medical Systems (MMSI) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 26.4% against the industry's decline of 1%. The S&P 500 Composite has risen 16.3% in the same period. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. South Jordan, UT-headquartered Merit Medical provides various peripheral and cardiac intervention products to cure cardiac condit ...

For the quarter ended June 2024, Merit Medical (MMSI) reported revenue of $338 million, up 5.6% over the same period last year. EPS came in at $0.92, compared to $0.81 in the year-ago quarter. The reported revenue represents a surprise of +0.92% over the Zacks Consensus Estimate of $334.94 million. With the consensus EPS estimate being $0.88, the EPS surprise was +4.55%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...

Merit Medical (MMSI) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $0.81 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.71 per share when it actually produced earnings of $0.77, delivering a surprise of 8.45%. Over the last f ...

Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6% Constant currency revenue* up 6.6% Constant currency revenue, organic,* up 5.0% GAAP operating margin of 13.6%, compared to 9.0% in prior year period Non-GAAP operating margin* of 20.1%, compared to 19.1% in prior year period GAAP EPS $0.61, up 75.7% Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current quarter compared with the same prior year period unless otherwise specified. * The ...

Shares of Merit Medical Systems, Inc. (MMSI) scaled a new 52-week high of $86.44 on Jun 28, before closing the session slightly lower at $85.95. Over the past year, this Zacks Rank #3 (Hold) stock has gained 4.2% against the 2.2% decline of the industry. The S&P 500 has witnessed 23.7% growth in the said time frame. Over the past five years, the company registered earnings growth of 15.2% compared with the industry's 12.9% rise. The company's long-term expected growth rate of 10.8% compares with the industr ...

| --- | --- | |--------------------------------------------------------|--------------------------------------------------------------------------| | | | | PR/Media Inquiries: Sarah Comstock Merit Medical | Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR | | +1-801-432-2864 | +1-443-213-0509 | | sarah.comstock@merit.com | mike.piccinino@westwicke.com | GERD is a digestive disorder that occurs when the lower esophageal sphincter doesn't tighten correctly, allowing acid from the stomach to enter ...

SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million. EndoGastric Solutions' EsophyX® Z+ device delivers a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD. About EsophyX Z+ Treatment The assets acquired from EndoGastric S ...

GERD is a digestive disorder that occurs when the lower esophageal sphincter doesn't tighten correctly, allowing acid from the stomach to enter the esophagus. When this occurs chronically, it can result in serious health conditions, such as esophageal damage and cancer. The EsophyX Z+ device treats GERD by restoring the body's reflux barrier. * Non-GAAP net income; non-GAAP earnings per share; non-GAAP gross margin; non-GAAP operating margin and constant currency revenue are non-GAAP financial measures. A d ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Zacks Premium also includes the Zacks Style Scores. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. The Style Scores are broken down into four categories: Value investors love finding good ...